The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,799.50
Bid: 1,796.00
Ask: 1,796.50
Change: 19.00 (1.07%)
Spread: 0.50 (0.028%)
Open: 1,784.00
High: 1,799.50
Low: 1,780.00
Prev. Close: 1,780.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

FTSE 100 slips as ex-dividend trades weigh, Rolls-Royce soars

Thu, 23rd Feb 2023 17:10

Rolls-Royce jumps on upbeat forecast

*

Major banks and healthcare stocks trade ex-div

*

FTSE 100 down 0.3%, FTSE 250 adds 0.6%

Feb 23 (Reuters) - The FTSE 100 ended lower on Thursday, as several banking and healthcare heavyweights traded ex-dividend, although shares of Rolls-Royce zoomed more than 20% after the aeroplane engine maker reported upbeat results.

The blue-chip index was down 0.3%, declining for a third straight session.

Shares of banks including Barclays and Standard Chartered and healthcare majors AstraZeneca and GSK slipped as they traded without entitlement for dividend payout.

Limiting losses on the FTSE 100 however Rolls-Royce surged 23.7% to post its biggest percentage gain in more than two years after the company's CEO forecast more profit growth in 2023.

"There was a lot of concern coming into this year generally about margins, results and (if) companies would be able to maintain their margins," said Caroline Simmons, UK chief investment officer at UBS Global Wealth Management.

"But what we've been seeing is so far the results have been broadly okay."

The FTSE 250 midcap index rose 0.6%, with John Wood Group Plc jumping 29.0% to the top of the index after the oilfield services and engineering firm said it received and rejected takeover proposals from Apollo Global Management.

Meanwhile, Bank of England interest rate-setter Catherine Mann said that it was

too soon to say

the risks posed by the surge in inflation last year had eased and that the central bank should continue to raise borrowing costs.

"Right now, the main driver for equities is just this reassessment of whether we have in fact priced peak rates, even if it means the recession is not coming," said Michael Metcalfe, head of macro strategy at State Street Global Markets.

Strong economic data in January has shaken investor confidence, he added.

Among other single stocks, Mondi fell 4.8% after the paper packaging company gave a cautious outlook.

Drax Group lost 3.7% as analysts said falling forward sales could hit the power generation firm's core earnings in 2024. The company posted annual profit that beat analysts' expectation. (Reporting by Shashwat Chauhan and Shristi Achar A in Bengaluru; editing by Uttaresh.V, Eileen Soreng and Andrew Heavens)

More News
17 Jan 2024 08:05

GSK raises £978m through Haleon share sale

(Sharecast News) - GSK said on Wednesday that it has raised around £978m from the sale of shares in Haleon.

Read more
17 Jan 2024 07:46

LONDON BRIEFING: UK inflation surprises as unexpectedly rises to 4.0%

(Alliance News) - Stocks in London are called to open lower on Wednesday, following some hotter-than-expected consumer price data from the UK.

Read more
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more
16 Jan 2024 17:04

GSK to sell GBP1 billion worth of Haleon shares as trims stake again

(Alliance News) - GSK PLC on Tuesday said it intends to sell around GBP1.00 billion worth of shares in Haleon PLC, as it continues to reduce its shareholding in the Weybridge, Surrey-based consumer healthcare spin-off.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
16 Jan 2024 07:37

LONDON BRIEFING: UK jobless rate sticks at 4.2% but pay growth slows

(Alliance News) - Stocks in London are called to open lower on Tuesday, following data showing that the UK jobless rate was unchanged at 4.2% as pay growth slowed.

Read more
15 Jan 2024 08:42

Zantac fallout unfairly weighing on GSK, says Shore Capital

(Sharecast News) - Shore Capital has raised its target price and maintained a positive stance on biopharma giant GSK, saying that worries about the potential cost of Zantac litigation are unfairly weighing on the stock.

Read more
10 Jan 2024 09:35

LONDON BROKER RATINGS: BofA cuts Ashtead; UBS likes 3i Group

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
10 Jan 2024 08:25

GSK says Nucala gets green light in China for asthma treatment

(Alliance News) - GSK PLC on Wednesday said Nucala has been approved in China for the treatment of severe asthma.

Read more
10 Jan 2024 07:22

GSK's Nucala gets fresh approval in China

(Sharecast News) - GSK announced on Wednesday that the China National Medical Products Administration (NMPA) has granted approval for 'Nucala', or mepolizumab, as an add-on maintenance treatment for severe eosinophilic asthma in adults and adolescents aged 12 years and older.

Read more
9 Jan 2024 16:22

London close: Stocks finish red after choppy session

(Sharecast News) - London stocks had turned back into the red by the close on Tuesday, with recruitment firms and asset managers pacing the declines after some disappointing corporate updates.

Read more
9 Jan 2024 08:03

TOP NEWS: GSK to buy Aiolos Bio for up to USD1.4 billion

(Alliance News) - GSK PLC on Tuesday said it will acquire asthma drug developer Aiolos Bio Inc for USD1 billion upfront, as well as up to USD400 million in certain success-based milestone payments.

Read more
9 Jan 2024 07:16

GSK buys respiratory drug maker Aiolos for $1bn

(Sharecast News) - GSK said it was buying Aiolos, a clinical-stage biopharmaceutical company focused on treatment of respiratory and inflammatory conditions, for up to $1.4bn (£1.1bn).

Read more
8 Jan 2024 23:39

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.